idecabtagene vicleucel
Selected indexed studies
- Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. (N Engl J Med, 2021) [PMID:33626253]
- Standard-of-care idecabtagene vicleucel for relapsed/refractory multiple myeloma. (Blood, 2025) [PMID:40198886]
- Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma. (J Clin Oncol, 2025) [PMID:39965175]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. (2021) pubmed
- Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma. (2022) pubmed
- Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium. (2023) pubmed
- Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment. (2024) pubmed
- Standard-of-care idecabtagene vicleucel for relapsed/refractory multiple myeloma. (2025) pubmed
- Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma. (2025) pubmed
- Idecabtagene vicleucel for relapsed/refractory multiple myeloma: a review of recent advances. (2022) pubmed
- PMID:37797149 (2022) pubmed
- Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial. (2023) pubmed
- Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter study. (2025) pubmed